TheraRadar
← Back
Data updated: Jul 17, 2026

DELCOR ASSET CORP

Specialty
Pharmaceuticals

DELCOR ASSET CORP is a specialty pharmaceutical company with 7 FDA-approved products.

1951
Since
7
Drugs
-
Trials
0
New Drugs (2yr)

DELCOR ASSET CORP's Key Drugs

DELCOR ASSET CORP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

DELCOR ASSET CORP's Recent FDA Approvals

New NDA/BLA approvals for DELCOR ASSET CORP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

DELCOR ASSET CORP's Therapeutic Areas

Disease areas where DELCOR ASSET CORP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

DELCOR ASSET CORP Pipeline Snapshot

Active clinical trials for DELCOR ASSET CORP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling